Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia

Clinical Cardiology

Volumn 24, Issue 10 SUPPL., 2001, Pages

  Isaacsohn, J ^a   Insull W , Jr ^a   Stein, E ^a   Kwiterovich, P ^a   Ma, P ^a   Brazg, R ^a   Dujovne, C A ^a   Shan, M ^a   Shugrue Crowley, E ^a   Ripa, S ^a   Tota, R ^a  

^a Medpace ^*  (United States)

Author keywords

Cerivastatin; Hypercholesterolemia; Low density lipoprotein; Safety; Statins

Indexed keywords

AMINOTRANSFERASE; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; RESIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME;

EID: 0034808236     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960240902     Document Type: Article

References (31)

1. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms
2. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
3. Assessing the benefits of lipid-lowering therapy
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group
5. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program
6. Lowering LDL cholesterol: Questions from recent meta-analyses and subset analyses of clinical trial. Data Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting
7. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
8. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention study
9. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators
10. Summary of the Second Report of the National Cholesterol Education Programs (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
11. Cerivastatin: A pooled efficacy analysis
12. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: A multinational, randomised, double-blind study
13. Comparison of cerivastatin 0.3 mg to pravastatin 20 mg, and cerivastatin 0.4 mg to pravastatin 40 mg in 1,030 hypercholesterolemic patients
14. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. Comparison of long-term efficacy and safety of cerivastatin versus pravastatin in primary hypercholesterolaemia
17. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
18. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolemia: The pivotal placebo-controlled clinical trial
19. Cerivastatin in primary hyperlipidemia: A multicenter analysis of efficacy and safety
20. Cerivastatin in primary hyperlipidemia - A multicenter analysis of efficacy and safety
21. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
22. Extending therapy options in treating lipid disorders: A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor
23. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
24. Effect of simvastatin on lp(a) concentrations
25. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a
26. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome
27. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial
28. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins
29. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia
30. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients